Compare GEO & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | ADPT |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.5B |
| IPO Year | 1996 | 2019 |
| Metric | GEO | ADPT |
|---|---|---|
| Price | $26.82 | $24.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $39.00 | $29.81 |
| AVG Volume (30 Days) | ★ 2.0M | 2.0M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 727.27 | 63.89 |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $2,263,420,000.00 | $276,976,000.00 |
| Revenue This Year | $13.78 | $5.94 |
| Revenue Next Year | $8.73 | $22.42 |
| P/E Ratio | $42.51 | ★ N/A |
| Revenue Growth | 3.85 | ★ 54.77 |
| 52 Week Low | $12.51 | $12.00 |
| 52 Week High | $33.17 | $30.74 |
| Indicator | GEO | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 33.22 | 41.12 |
| Support Level | $22.29 | $23.73 |
| Resistance Level | $32.56 | $26.51 |
| Average True Range (ATR) | 1.38 | 1.54 |
| MACD | -0.43 | -0.33 |
| Stochastic Oscillator | 10.84 | 6.68 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services. The company operates in U.S, Australia and South Africa.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.